Copyright
©The Author(s) 2021.
World J Clin Cases. Feb 26, 2021; 9(6): 1293-1303
Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1293
Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1293
Table 1 Baseline clinical characteristics of the study participants
| Propofol group (n = 40) | Etomidate group (n = 40) | P value | |
| Male sex, n (%) | 21 (52.5%) | 23 (57.5%) | 0.651 |
| Age (years), mean ± SD | 56.7 ± 6.6 | 53.6 ± 6.1 | 0.452 |
| Weight (kg), mean ± SD | 64.6 ± 12.5 | 66.4 ± 16.3 | 0.084 |
| Height (cm), mean ± SD | 165.7 ± 11.9 | 163.4 ± 13.3 | 0.732 |
| Type of surgery, n (%) | |||
| Gastrointestinal | 26 (65.0%) | 23 (57.5%) | 0.946 |
| Hepatobiliary | 8 (20.0%) | 10 (25.0%) | 0.783 |
| Thyroid | 6 (15.0%) | 7 (17.5%) | 0.562 |
- Citation: Dai ZL, Cai XT, Gao WL, Lin M, Lin J, Jiang YX, Jiang X. Etomidate vs propofol in coronary heart disease patients undergoing major noncardiac surgery: A randomized clinical trial. World J Clin Cases 2021; 9(6): 1293-1303
- URL: https://www.wjgnet.com/2307-8960/full/v9/i6/1293.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i6.1293